AKAMIS BIO
Akamis Bio is a clinical-stage oncology company whose mission is to use its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to improve the lives of cancer patients. To accomplish this goal, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics that will allow a patient's immune system to recognize, attack, and clear their cancer.
AKAMIS BIO
Industry:
Biotechnology Health Care Oncology Therapeutics
Founded:
2010-01-01
Address:
Abingdon, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.akamisbio.com
Total Employee:
51+
Status:
Active
Contact:
+44 (0)1235 835328
Email Addresses:
[email protected]
Total Funding:
132.49 M USD
Technology used in webpage:
SPF Euro DMARC Microsoft Exchange Online Office 365 Mail Google Google Cloud Cloudflare DNS Google Cloud Global Multi-Region Google Cloud Iowa
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
EpicentRx Inc
EpicentRx Inc is a clinical-stage immuno-oncology company.
IMV
IMV is a clinical-stage immuno-oncology company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
NovaBiotics
NovaBiotics Ltd is a clinical-stage biotechnology company.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-12-16 | Hybrid BioSystems | Hybrid BioSystems acquired by Akamis Bio | N/A |
Investors List
Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy investment in Convertible Note - Akamis Bio
Westlake Village BioPartners
Westlake Village BioPartners investment in Convertible Note - Akamis Bio
ARCH Venture Partners
ARCH Venture Partners investment in Convertible Note - Akamis Bio
Salica
Salica investment in Secondary Market - Akamis Bio
IP Group
IP Group investment in Venture Round - Akamis Bio
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Venture Round - Akamis Bio
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series C - Akamis Bio
Imperial Innovations
Imperial Innovations investment in Series C - Akamis Bio
Woodford Investment Management
Woodford Investment Management investment in Series C - Akamis Bio
Invesco
Invesco investment in Series C - Akamis Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-11 | PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer |
| 2020-03-05 | PsiOxus lures Lillie from Merck to fill CMO position |
Official Site Inspections
http://www.akamisbio.com Semrush global rank: 13.36 M Semrush visits lastest month: 78
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Akamis Bio"
About Us | Akamis Bio | Tumor Gene Therapy
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. To achieve that …See details»
Leadership | Akamis Bio | Tumor Gene Therapy
Akamis Bio (UK Office) 4-10, The Quadrant, Abingdon Science Park Barton Lane, Abingdon Oxfordshire, OX14 3YS United Kingdom +44 (0)1235 835328See details»
Akamis Bio - LinkedIn
Akamis Bio | 7,358 followers on LinkedIn. Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer | Akamis is a clinical-stage oncology company whose mission is to ...See details»
Akamis Bio - LinkedIn
Akamis Bio | 7,416 followers on LinkedIn. Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer | Akamis is a clinical-stage oncology company whose …See details»
Akamis Bio - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +44 (0)1235 835328 Akamis Bio is a clinical-stage oncology company whose mission is to use its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to …See details»
Akamis Bio Announces $30 Million Financing, Provides …
Jan 5, 2023 Company: Kate Wright Akamis Bio +44 (0)1235 835328 [email protected] Media: Mike Beyer Sam Brown Inc. Healthcare Communications +1 (312) 961-2502 [email protected]See details»
Akamis Bio Announces $30 Million Financing, Provides ... - BioSpace
Jan 5, 2023 In conjunction with the corporate name change, the company has launched a new website at www.akamisbio.com. The $30 million convertible note financing was co-led by new …See details»
Akamis Bio Company Profile 2024: Valuation, Funding & Investors
Akamis Bio General Information Description. Operator of a clinical-stage oncology company intended to develop cancer gene therapies. The company focuses on immunobiology …See details»
Akamis Bio Strengthens Leadership Team with Key Executive …
[email protected]. Media Contact: Mike Beyer. Sam Brown Inc. Healthcare Communications +1 (312) 961-2502. [email protected]. Investor Contact: Chelcie …See details»
Akamis Bio - Overview, News & Similar companies | ZoomInfo.com
Jul 6, 2023 Akamis Bio has announced that Oliver Rosen has joined the organization as Chief Medical Officer. Previously, Rosen served as President & Chief Medical Officer for …See details»
Akamis Bio, Parker Institute for Cancer Immunotherapy, and
Feb 16, 2023 CAMBRIDGE, Mass. & OXFORD, England--(BUSINESS WIRE)-- Akamis Bio, a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T …See details»
Akamis Bio Strengthens Leadership Team with Key Executive …
Jul 6, 2023 Company Contact: [email protected] Media Contact: Mike Beyer Sam Brown Inc. Healthcare Communications +1 (312) 961-2502 [email protected] …See details»
PsiOxus is no more: Meet Akamis Bio - Fierce Pharma
Jan 6, 2023 Less than a week into 2023, and we already have a biotech name change as PsiOxus Therapeutics becomes Akamis Bio. | Less than a week into 2023, and we already …See details»
Akamis Bio Announces $30 Million Financing, Provides Clinical …
January 05, 2023 08:00 AM Eastern Standard Time. CAMBRIDGE, Mass. & OXFORD, England--(BUSINESS WIRE)--Akamis Bio (formerly PsiOxus Therapeutics), a clinical-stage oncology …See details»
Akamis Bio, Parker Institute for Cancer Immunotherapy, and …
Feb 16, 2023 Company: Kate Wright Akamis Bio +44 (0)1235 835328 [email protected] Media: Mike Beyer Sam Brown Inc. Healthcare …See details»
Akamis Bio Announces $30 Million Financing, Provides
On January 5, 2023 Akamis Bio (formerly PsiOxus Therapeutics), a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform to positively …See details»
Our Technology | Akamis Bio | Tumor Gene Therapy
Despite tremendous advances over the last decade, numerous obstacles remain for immuno-oncology modalities (e.g., checkpoint inhibitors, antibody drug conjugates, bispecific T-cell …See details»
Akamis Bio Highlights Data Showing Potential of its Adenovirus …
Oct 3, 2023 Company Contact: [email protected] Media Contact: Mike Beyer Sam Brown Inc. Healthcare Communications +1 (312) 961-2502 [email protected] …See details»
Our Pipeline | Akamis Bio | Tumor Gene Therapy
Akamis Bio has a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active …See details»